Minerva Neurosciences (NASDAQ ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Trading Halts

Minerva Neurosciences (NERV) Phase 3 Trial of Roluperidone for Treatment of Negative Symptoms in Schizophrenia Did Not Meet Its Primary and Key Secondary EndpointsMay 29, 2020 9:21 AM Minerva Neurosciences Announces Results From Phase 3 Trial of Roluperidone (MIN-101) for Treatment of Negative Symptoms in SchizophreniaMay 29, 2020 9:21 AM Minerva Neurosciences Announces Results From Phase 3 Trial of Roluperidone (MIN-101) for Treatment of Negative Symptoms in SchizophreniaMay 29, 2020 9:20 AM Minerva Neurosciences (NERV) Halted, News PendingMay 29, 2020 9:15 AM